BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1377 related articles for article (PubMed ID: 28052977)

  • 1. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
    Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
    Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
    Cannon JA; Shen L; Jhund PS; Anand IS; Komajda M; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2016 Aug; 18(8):1021-31. PubMed ID: 27194023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
    Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
    Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
    Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
    Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
    Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
    J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
    Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
    Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irbesartan in patients with heart failure and preserved ejection fraction.
    Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
    N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
    Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
    Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.
    Zile MR; Gottdiener JS; Hetzel SJ; McMurray JJ; Komajda M; McKelvie R; Baicu CF; Massie BM; Carson PE;
    Circulation; 2011 Dec; 124(23):2491-501. PubMed ID: 22064591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
    Lam CS; Carson PE; Anand IS; Rector TS; Kuskowski M; Komajda M; McKelvie RS; McMurray JJ; Zile MR; Massie BM; Kitzman DW
    Circ Heart Fail; 2012 Sep; 5(5):571-8. PubMed ID: 22887722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
    Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
    Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
    Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
    J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study.
    Donal E; Lund LH; Oger E; Hage C; Persson H; Reynaud A; Ennezat PV; Bauer F; Drouet E; Linde C; Daubert C;
    Eur J Heart Fail; 2015 Jul; 17(7):680-8. PubMed ID: 26033771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
    Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
    J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.